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Abstract 
Boron Neutron Capture Therapy (BNCT) is a binary 
cancer therapy particularly well-suited to treating 
aggressive tumours that exhibit a high degree of 
infiltration of the surrounding healthy tissue. Such 
tumours, for example of the brain and lung, provide some 
of the most challenging problems in oncology. The first 
element of the therapy is boron-10 which is preferentially 
introduced into the cancerous cells using a carrier 
compound. Boron-10 has a very high capture cross-
section with the other element of the therapy, thermal 
neutrons, resulting in the production of a lithium nucleus 
and an alpha particle which destroy the cell they are 
created in. However, a large flux of neutrons is required 
and until recently the only source used was a nuclear 
reactor. In Birmingham, studies of an existing BNCT 
facility using a 2.8 MeV proton beam and a solid lithium 
target have found a way to increase the beam power to a 
sufficient level to allow clinical trials, while maintaining 
the target solid. In this paper, we will introduce BNCT, 
describe the work in Birmingham and compare with other 
accelerator-driven BNCT projects around the World. 
BNCT 
BNCT is a form of radiotherapy in which a stable 
isotope of boron (boron-10) is bound to a non-toxic 
carrier molecule (such as 1-p-borono-phenyl alanine 
(BPA)) which is preferentially absorbed by tumour. When 
the tissues are exposed to low energy neutrons, the 
following reaction occurs: 
MeVLiHeBn 8.274101   
The alpha particle and lithium nucleus produced have 
mean free paths which are the same as the cell sizes. 
Thus, they deposit most of their energy in the cancerous 
cell in which they are created, thereby destroying it. 
Provided a sufficient boron concentration exists in the 
tumour cells, the high neutron capture cross-section of 10B 
ensures that most of the energy from the neutron beam is 
deposited where it is needed and the damage to healthy 
tissue surrounding the tumour is minimised compared to 
other therapies (see figure 1). In addition, it means BNCT 
does not rely heavily on imaging to define the target 
volume to be treated so it is particularly well suited for 
tumours where the disease is infiltrating into the healthy 
tissue belonging to vital organs. Such tumours are some 




Figure 1: Comparison between the dose delivered to 
tumour and healthy cells using BNCT for realistic uptakes 
on the carrier compound BPA. 
 
A number of trials of BNCT have been carried out, 
focussing on a highly aggressive type of brain tumour 
called a glioblastoma multiforme (GBM). This is the most 
common type of primary, malignant brain tumour, with 
about 13000 people being diagnosed in Europe each year. 
Data on progression free survival of glioma patients 
treated in Japan with an approach which combines BNCT 
with x-ray radiotherapy can be compared with results 
from the highly regarded randomised trial performed by 
Stupp et al [1] (the current state-of-the-art). This study 
employed a drug called temozolomide and the most 
striking outcome was an approximate doubling of the 
number of patients surviving 2 years from around 12% to 
25%. The data from Tsukuba [2] on BNCT shows a 
further factor of 2 improvement in 2 year survival, to 
45.7%. It should be noted, however, that the number of 
patients is extremely small (12 in the study of Yamamoto 
et al) and these results will need to be reproduced in a 
larger population before any conclusions can be drawn. 
It is important to note that the improved success shown 
in studies which combine BNCT with x-ray therapy is 
entirely to be expected from the data recently published in 
Birmingham [3]. This shows that BPA uptake is 
dominated by a common transporter system, the L-amino 
acid transporter-1 (LAT-1). Further (see figure 2): 
a) LAT-1 expression is shown in 30-90 % of tumour 
cells (i.e. a high proportion but < 100%) 
b) Indices of proliferation are lower (i.e. in a real 
tumour not all cells are actively dividing). 
At present the research on LAT-1 is aimed at developing a 
better understanding of BPA-based BNCT, but in time it 
could develop into a selection methodology for patients 
who will benefit most from this new treatment. It is, 
however, already clear that since not all tumour cells 
express LAT-1, and BPA uptake is mediated by LAT-1, 
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any treatment strategy based on a single delivery of BPA-
based BNCT alone will not succeed. An approach which 
combines BNCT with a powerful treatment that targets all 
cells (eg x-ray radiotherapy) then looks optimal. 
 
Figure 2: LAT-1 expression and proliferation index of the 
highest rages (Grade IV) human gliomas. 
 
In addition to GBM, BNCT has found clinical utility in 
the treatment of recurrent head and neck cancer (mainly 
Squamous Cell Carcinoma (SCC)) where published data 
from Helsinki shows that this treatment is well tolerated 
and capable of providing good life extension [4]. BNCT 
has also been shown to have potential in the treatment of 
metastatic colon cancer in the liver, primary and 
metastatic melanoma and lung cancer. 
NEUTRON PRODUCTION 
Producing a sufficient flux of neutrons with the correct 
energy is a particular problem with BNCT. The 
requirement is a flux of around 109 epithermal 
neutrons/cm2/s for a session of less than 30 minutes. In 
addition, as well as being mainly at epithermal energies, 
the beam should not also have neutrons above 1 MeV, as 
these add to the dose to healthy tissue in an uncontrollable 
manner. Currently, the only source used is a (usually 
research) nuclear reactor. Reactors in Japan, the US, the 
Netherlands, Finland and Argentina have or are being 
used for BNCT studies [5]. 
Nuclear reactors are clearly not ideal locations for 
treating patients, some of whom may be very unwell. This 
is part of reason why so few patients have so far been 
treated with the therapy. It is possible to make the 
neutrons with particle accelerators, but here the beam 
requirements create significant technical problems. In 
particular, the requirement for a large flux of epithermal 
neutrons, after moderation, with no or a very limited flux 
of neutrons above 1 MeV, requires a low energy proton 
beam (< 10 MeV). This means that the best neutron 
production reactions to use are beams of either protons or 
deuterons on lithium or beryllium targets (see figure 3). 
Producing a sufficient neutron flux then requires a beam 
power of at least 12 kW and probably more like 20 kW. 
This then makes heat removal and avoiding/handling 
blistering of the target the most difficult aspects of 
accelerator production, particularly with a lithium target. 
Each of the options, with examples, is discussed below. 
 
Figure 3: Reactions for the production of neutrons at low 
beam energy 
Solid Lithium Target 
Protons at 3 MeV penetrate only 400 µm in to lithium, 
so the power from the beam is deposited in a very thin 
layer. Further, the melting point of lithium is only 181 oC, 
so preventing it melting is the most difficult aspect of this 
target. In almost all cases, the lithium is bonded to a 
copper or aluminium backing and the backing is cooled 
using light or heavy water. As 7Li(p,n)7Be reaction has a 
threshold at 1.88 MeV, ideally what is required is a very 
thin layer of lithium, so that the remaining and unuseful 
beam power is deposited directly in the copper. However, 
tests of such targets have shown that the lithium tends to 
blister and separate from the backing at the required beam 
powers [6]. 
An alternative approach has been taken in the 
University of Birmingham in the UK. This employs a 0.7 
mm thick disk of lithium of diameter 4 cm firmly bonded 
to a copper backing. A Dynamitron accelerator, run at 2.8 
MeV, is mounted vertically and accelerates the proton 
beam downwards. The copper is cooled from below using 
a submerged heavy water jet [7]. The beam is steered in 
an annulus around the target using two steering magnets. 
With this system, the temperature in the lithium from the 
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4.2 kW beam is kept below the melting point. Further, no 
blistering of the target is seen.  
A 40 cm thick moderator and reflector system has been 
designed to deliver an epithermal neutron beam to a 
patient at right angles to the beam direction. With this 
arrangement, no neutrons above 1 MeV are produced in 
the direction of the patient. However, with the current 
beam power, the treatment time is too long and an 
increase by a factor of 2.5 to 3 is required to make this 
tolerable for clinical trials. 
A number of studies have been done to determine how 
to make this increase. These include optimisation studies 
of the moderator and the target cooling. This work is on-
going, but has produced encouraging results. The ultimate 
test will need an upgrade to the Dynamitron to deliver the 
required beam current. This has also been studied and 
looks feasible. A proposal has been submitted to 
implement the changes and undertake clinical trials of the 
therapy. 
Liquid Lithium Target 
The alternative to a solid lithium target is a liquid one. 
A number of studies of flowing liquid lithium targets for 
BNCT are taking place. The advantages of this over a 
solid target are clear: the heat deposited is carried away 
by the lithium, which can be cooled outside of the target 
and the effective volume of lithium exposed to the beam 
is much larger, so the damage resulting from it is spread 
over this larger volume. However, such a target is more 
complex than a simple solid target and requires the 
infrastructure to prepare, circulate and cool the lithium. In 
addition, there is a significant health and safety risk in a 
hospital environment. Further, the flow rate must be 
sufficient to maintain the temperature below the boiling 
point at the pressure in the target region, typically about 
340oC. 
As an example, a target made from a flowing film of 
liquid lithium has been studied in Osaka University in 
Japan [8]. The plan is for a 0.5 mm thick film of 50 mm 
width and 50 mm length for use with a beam of 3 MeV 
and a current of up to 20 mA. Tests have demonstrated 
that a stable flow should be possible at a flow rate of 30 
m/s, which will be sufficient to keep the lithium 
temperature below the required level. It is now planned to 
build a demonstration project using this target. 
Beryllium Target 
Beryllium has the advantage of higher melting point, 
higher thermal conductivity and the ability to be directly 
cooled with water. However, as shown by Figure 3, higher 
proton beam energies are required for the same neutron 
yield. This increases both the cost and complexity of the 
accelerator. In addition, the mean neutron energy is 
higher, leading to the need for more moderation. This 
places the patient further from the source and hence 
increases the total neutron yield required. In addition, 
there is a significant contribution of high energy neutrons. 
A BNCT facility has recently started trials at the Kyoto 
University Research Reaction Institute (KURRI) using a 
beryllium target [9]. They employ a 30 MeV cyclotron 
which can accelerate a 2 mA H- ion beam, though 
typically 1 mA is used. The beam spot is increased to 80 
mm diameter and steered around the 160 mm diameter 
target using scanning magnets. The thickness of the 
beryllium is set to be slightly less than the range of 30 
MeV protons. It is cooled from behind using water. The 
neutron energy peaks at around 1 MeV so the target is 
followed by a moderator system to reduce this to the 
required energy of around 10 keV. The measured flux of 
thermal neutrons in a phantom is 1.8x109 cm-2s-1. As 
expected, however, the flux of high energy neutrons 
exceeds the target value. 
To reduce the flux of high energy neutrons, an 
alternative approach is being taken in Argentina [10]. The 
plan there is a use a low energy deuteron beam of 1.4 
MeV and a very thin beryllium target, around 8 µm thick, 
which has the effect of supressing the production of high 
energy neutrons. A facility to test this concept and to start 
producing neutrons is under construction. 
CONCLUSIONS 
Boron Neutron Capture Therapy has shown great 
potential for the treatment of certain types of aggressive 
tumours that are otherwise difficult to treat, in particular 
those that infiltrate the surrounding healthy tissue. The 
main difficulty in the therapy is producing a sufficient 
flux of epithermal neutrons to keep the treatment session 
time to a tolerable level with an accelerator, while also 
controlling the rate of high energy neutrons. A number of 
projects around the world are pursuing three basic options 
to achieve these goals. One has started treatment. 
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